![Gregory S. Moss](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Historial de carrera de Gregory S. Moss
Antiguos cargos conocidos de Gregory S. Moss.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
KADMON HOLDINGS, INC. | Oficial de Cumplimiento | 30/08/2019 | 01/06/2022 |
Consejero General | 30/08/2019 | 01/06/2022 | |
Corporate Officer/Principal | 01/01/2015 | 30/08/2019 | |
Secretario Corporativo | 30/08/2019 | 01/06/2022 | |
MEIRAGTX HOLDINGS PLC | Director/Miembro de la Junta | 01/05/2018 | 19/06/2019 |
MeiraGTx Ltd.
![]() MeiraGTx Ltd. Pharmaceuticals: MajorHealth Technology MeiraGTx Ltd. engages in the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. The company was founded on March 20, 1991 and is headquartered in London, the United Kingdom. | Oficial de Cumplimiento | 01/04/2015 | 01/12/2016 |
Consejero General | 01/04/2015 | 01/12/2016 |
Formación de Gregory S. Moss.
Macquarie University | Graduate Degree |
Estadísticas
Internacional
Islas Caimán | 2 |
Estados Unidos | 2 |
Reino Unido | 2 |
Operativa
Compliance Officer | 2 |
General Counsel | 2 |
Director/Board Member | 1 |
Sectorial
Health Technology | 4 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
MEIRAGTX HOLDINGS PLC | Health Technology |
Empresas privadas | 2 |
---|---|
Kadmon Holdings, Inc.
![]() Kadmon Holdings, Inc. BiotechnologyHealth Technology Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY. | Health Technology |
MeiraGTx Ltd.
![]() MeiraGTx Ltd. Pharmaceuticals: MajorHealth Technology MeiraGTx Ltd. engages in the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. The company was founded on March 20, 1991 and is headquartered in London, the United Kingdom. | Health Technology |
- Bolsa de valores
- Insiders
- Gregory S. Moss
- Experiencia